thymus extract raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-06-30 and is reviewed periodically as new material appears.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
=== Bibliography === Algar, Hamid (1989). "BEKTĀŠĪYA". Encyclopaedia Iranica. Vol. IV. pp. 118–122. Doja, Albert. 2006. "A political history of Bektashism from Ottoman Anatolia to Contemporary Turkey." Journal of Church and State 48 (2): 421–450. doi=10.1093/jcs/48.2.423. Doja, Albert. 2006. "A political history of Bektashism in Albania." Politics, Religion & Ideology 7 (1): 83–107. doi=10.1080/14690760500477919. Elsie, Robert (2001). A Dictionary of Albanian Religion, Mythology and Folk Culture. New York: New York University Press. ISBN 978-1-85065-570-1. Nicolle, David; UK (1995). The Janissaries (5th). Osprey Publishing. ISBN 1-85532-413-X. Muhammed Seyfeddin Ibn Zulfikari Derviş Ali; Bektaşi İkrar Ayini, Kalan Publishing, Translated from Ottoman Turkish by Mahir Ünsal Eriş, Ankara, 2007 Turkish Saggau, Emil BH. "Marginalised Islam: Christianity's role in the Sufi order of Bektashism." In Exploring the Multitude of Muslims in Europe, pp. 183–197. Brill, 2018. Soileau, Mark (2014). "Conforming Haji Bektash: A Saint and His Followers between Orthopraxy and Heteropraxy." Die Welt des Islams 54, pp. 423-459
=== Early history === Some of the earliest records of human occupation of Billericay are the burial mounds in Norsey Wood, showing evidence of occupation in the Bronze and Iron Ages. Evidence of a Roman town, subsequently abandoned, were found on the high ground at Billericay School, just south of the High Street during excavations in 1970–71. There may also have been a small cavalry fort at Blunts Wall Farm.
== Structure == NFE2L2 and other genes, such as NFE2, NFE2L1 and NFE2L3, encode basic leucine zipper (bZIP) transcription factors. They share highly conserved regions that are distinct from other bZIP families, such as JUN and FOS, although remaining regions have diverged considerably from each other. NRF2 is a basic leucine zipper (bZip) transcription factor with a Cap "n" Collar (CNC) structure. NRF2 possesses seven highly conserved domains called NRF2-ECH homology (Neh) domains. From the N-terminus to the C-terminus, they are:
==== Other countries ==== In Canada, France, the Netherlands, and Germany, mescaline in raw form and dried mescaline-containing cacti are considered illegal drugs. However, anyone may grow and use peyote (Lophophora williamsii) as well as Echinopsis pachanoi and Echinopsis peruviana (San Pedro cactus) without restriction, as they are specifically exempt from legislation. In Canada, mescaline is classified as a schedule III drug under the Controlled Drugs and Substances Act, whereas peyote is exempt. In Russia, mescaline, its derivatives, and mescaline-containing plants are banned as narcotic drugs (Schedule I).
Sources: en.wikipedia.org
=== Pharmacokinetics === When inhaled, dimethocaine starts working in 10–30 minutes, with highest effects at 60–120 minutes and until 4–6 hours there is a period of action with the 'after-effects'. The after effects include fatigue and slight mental impairment.
Action – Batman: Arkham City Artistic Achievement – Rayman Origins Audio Achievement – Battlefield 3 Best Game – Portal 2 Debut Game – Insanely Twisted Shadow Planet Family – LittleBigPlanet 2 Game Design – Portal 2 Game Innovation – LittleBigPlanet 2 Mobile & Handheld – Peggle HD Online – Browser – Monstermind Online Multiplayer – Battlefield 3 Original Music – L.A. Noire Performer – Mark Hamill (as The Joker, Batman: Arkham City) Sports/Fitness – Kinect Sports: Season Two Story – Portal 2 Strategy – Total War: Shogun 2 BAFTA Ones To Watch Award (in association with Dare to Be Digital) – Tick Tock Toys GAME Award of 2011 – Battlefield 3 Special – Markus Persson
Maui Mallard in Cold Shadow – originally released as Donald in Maui Mallard (Japanese: Donald Duck no Maui Mallard (ドナルドダックのマウイマラード)) – is a platforming video game developed and published by Disney Interactive. The game was released in Europe in November 1995, and in Brazil in spring 1997 for the Sega Mega Drive. It was also ported by Eurocom Entertainment Software to the SNES and released in North America in January 1997, in Europe mostly in autumn 1996 (although the SNES version was released in Germany at the end of 1995), and in Japan on December 20, 1996. A Microsoft Windows port was released in North America in November 1996. It was ported one last time to the Game Boy by Bonsai Entertainment Corp., released in North America in August 1998. The game stars Donald Duck in a metafictional role as duck detective Maui Mallard (a spoof of 1980s Hawaii-based TV detective, Magnum P.I. in name and appearance), who adopts the name "Cold Shadow" when he dresses up in ninja garb. In the North American versions of the game, all Donald Duck references are absent, and the protagonist is instead referred to as "Maui Mallard," as, according to composer Patrick Collins, the marketing team felt Donald Duck wasn't cool in the United States. Although the end of the game informed the player to look forward to Maui's next adventure, the planned sequel was cancelled. The game was rereleased on the Steam and GOG digital storefronts on May 17, 2019.
=== Disease association === Genetic variants and haplotypes (i.e., allotypes) of ERAP1 have been associated with a wide variety of inflammatory conditions, infectious diseases, and cancer. In particular, ERAP1 is a major risk gene identified in genome-wide association studies of MHC-I associated inflammatory conditions (or "MHC-I-opathies"), including Ankylosing Spondylitis, Bechet's disease, Birdshot Uveitis, and Psoriasis. In these conditions, ERAP1 is often in epistasis with the primary risk MHC-I allele. Other disease associations include insulin dependent Diabetes Mellitus and Multiple Sclerosis. Historically, ERAP1 gene associations were first reported in Hypertension. Emerging evidence links ERAP1 SNVs to cancer development, and susceptibility to infectious disease, such as ERAP1 SNVs that modify the resistance to influenza virus infection.
== Available forms == DBNPA’s available form is dependent on its intended industrial use. Its pure state is a crystalline solid, with a melting point of 123-126 °C. It is slightly soluble in water (1.5 g per 100 g at 25 °C) but dissolves readily in certain organic solvents like acetone and ethanol. For practical applications, DBPNA is most commonly used in the form of a mixture of 20% active solution combined with water and polyethylene glycol, which enhances its stability and handling in aqueous systems. Its solid forms are also available but are mainly used for packaging and storage; it is often packaged in containers within 25 kg woven bags in order to prevent moisture exposure in storage mechanisms.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.